Relevant Degree Programs
Complete these steps before you reach out to a faculty member!
- Familiarize yourself with the program requirements. You want to learn as much as possible from the information available to you before you reach out to a faculty member. Be sure to visit our graduate degree program listings and program-specific websites.
- Check whether the program requires you to seek commitment from a supervisor prior to submitting an application. For some programs this is an essential step while others match successful applicants with faculty members within the first year of study.
- Identify specific faculty members who are conducting research in your specific area of interest.
- Establish that your research interests align with the faculty member’s research interests.
- Read up on the faculty members in the program and the research being conducted in the department
- Familiarize yourself with their work, read their recent publications and past theses/dissertations that they supervised. Be certain that their research is indeed what you are hoping to study.
- Compose an error-free and grammatically correct email addressed to your specifically targeted faculty member, and remember to use their correct titles.
- Do not send non-specific, mass emails to everyone in the department hoping for a match.
- Address the faculty members by name. Your contact should be genuine rather than generic.
- Include a brief outline of your academic background, why you are interested in working with the faculty member, and what experience you could bring to the department.
- Highlight your achievements and why you are a top student. Faculty members receive dozens of requests from prospective students and you may have less than 30 seconds to peek someone’s interest.
- Provide documents that can help the faculty member gauge interest in you as a potential student. This could be a Statement of Intent, a Writing Sample, a list of publications or research endeavors.
- Demonstrate that you are familiar with their research
- Convey the specific ways you are a good fit for the program
- Convey the specific ways the program/lab/faculty member is a good fit for the research you are interested in/already conducting
- Be enthusiastic, but don’t overdo it.
G+PS regularly provides virtual sessions that focus on admission requirements and procedures and tips how to improve your application.
1. Clinical and Genomic Determinants of Early Metastasis in Synchronous Endometrial and Ovarian Cancers (MSc or PhD)
2. Development of Pre-Cancerous Mouse Models of Endometriosis (Post doc or PhD candidate with prior MSc/model experience)
- Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging (2018)
Naveena Singh and Asma Faruqi and Friedrich Kommoss and W Glenn McCluggage and Giorgia Trevisan and Janine Senz and Amy Lum and C Blake Gilks and Michael Anglesio
- Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes (2017)
Yi Kan Wang and Ali Bashashati and Michael S Anglesio and Dawn R Cochrane and Diljot S Grewal and Gavin Ha and Andrew McPherson and Hugo M Horlings and Janine Senz and Leah M Prentice and Anthony N Karnezis and Daniel Lai and Mohamed R Aniba and Allen W Zhang and Karey Shumansky and Celia Siu and Adrian Wan and Melissa K McConechy and Hector Li-Chang and Alicia Tone and Diane Provencher and Manon de Ladurantaye and Hubert Fleury and Aikou Okamoto and Satoshi Yanagida and Nozomu Yanaihara and Mis
Nature Genetics 49 (6) 856--865
- Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. (2015)
- Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. (2015)
- Recurrent DICER1 Hotspot Mutations in Endometrial Tumours And Their Impact on MicroRNA Biogenesis. (2015)
- Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. (2015)
- A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. (2014)
- A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. (2014)
- Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. (2014)
- Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. (2014)
- Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments. (2014)
- Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. (2013)
- Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. (2013)
- Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. (2013)
- Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. (2013)
- FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. (2013)
- Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. (2013)
- Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma. (2013)
- Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. (2013)
- Type-specific cell line models for type-specific ovarian cancer research. (2013)
- Benign serous ovarian tumour: a redefining moment? (2012)
- Cytokine gene expression signature in ovarian clear cell carcinoma. (2012)
- LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. (2012)
- Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. (2012)
- The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. (2012)
- Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. (2011)
- Copy number aberrations in benign serous ovarian tumors: a case for reclassification? (2011)
- Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. (2011)
- IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. (2011)
- Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. (2011)
- ARID1A mutations in endometriosis-associated ovarian carcinomas. (2010)
- Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. (2010)
- Profiling the cancer genome. (2010)
- Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. (2009)
- Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. (2008)
- The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. (2007)
- Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. (2006)
- Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. (2004)